nivolumab,ipilimumab
bms
['cm-9la', '9la']
 looks promising, but this is a cross-trial comparison to cm-9la, not actual h2h comparison in a prospective trial, right? it's time to do direct comparisons in rand trials when we have to make a choice among these regimens. to win, companies need to stop sidestepping this.
Med Onc,@CityofHope; VP Netwk Strategy AccessHope, Founder,@CancerGRACE; Web Ed,@JAMAOnc; Author/Ed, @UptoDate

Telemed/digital med fan. 
Disclosures @ website